The SEC announced today that it levied a complaint against Parallax Health Sciences and two top executives for making allegedly misleading statements about COVID-19-related products. Without admitting or denying the allegations, Parallax, its CEO Paul Arena, and CTO Nathaniel Bradley consented to judgments permanently enjoining them from future violations of the charged provisions and requiring […]